Bellicum Pharmaceuticals, a Houston, Texas-based developer of cell therapies to treat cancers and other serious, life-threatening diseases, secured an additional $14.7m in Series B financing.
Investors in the round, which now amounts to $34.4m, included current investors AVG Ventures and Remeditex Ventures.
The company intends to use the funds to expand clinical development of of its lead cellular immunotherapy product candidates.
Led by CEO Tom Farrell, Bellicum is advancing two lead clinical development programs in cellular transplants to reduce or eliminate Graft versus Host Disease, and in prostate cancer with a potentially more potent immunotherapy.
FinSMEs
07/01/2014
Related News
20/03/2012: Bellicum Pharmaceuticals Raises $20M in Series B Financing